Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Apixaban 5 mg (Dexa Medica) vs Eliquis in Healthy Volunteers
NCT06817811Phase 1Completed
- Sponsor
- Dexa Medica
- Start
- Apr 2021
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of apixaban in thromboembolism (2 arms), sponsored by Dexa Medica. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration at 48 hours and Maximum Plasma Concentration at 48 hours. Started Apr 2021; status: completed.
02
Drugs
apixaban
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT06817811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06817811.